Dr. Marijo Bilusic, MD, PhD, discusses the story of immunotherapy in prostate cancer, from the initial revolutionary breakthrough with sipuleucel-T (Provenge), through the research struggles with immune checkpoint inhibitors, to emerging strategies, such as vaccines, for converting immunologically “cold” tumors to immunologically “hot” tumors.
Dr. Bilusic is a medical oncologist and GU Site Disease Group Lead, Sylvester Comprehensive Cancer Center, Miami Florida. Prior to joining starting at Sylvester in 2021, he was an associate research physician at the NCI Medical Oncology Service/Genitourinary Malignancy Branch. Also at the NCI, he served as program director of the NIH Hematology Oncology Fellowship Program.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.